drugset
drugset / Trial / NCT01416623

A Phase I Study of Henatinib in Patients With Advanced Solid Malignancies

NCT01416623 ↗

Phase 1 Terminated 44 enrolled Jiangsu HengRui Medicine Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

Henatinib is a novel oral multitargeted tyrosine kinase inhibitor with antitumor and antiangiogenic activities. This study is designed to evaluate the safety and tolerability of Henatinib in patients with Advanced Solid Malignancies

Timeline

Start
2010-09
Primary completion
2012-12
Completion
2012-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Henatinib Small molecule 12.5 mg Oral
Subject Henatinib Small molecule 25 mg Oral
Subject Henatinib Small molecule 37.5 mg Oral
Subject Henatinib Small molecule 50 mg Oral
Subject Henatinib Small molecule 62.5 mg Oral
Subject Henatinib Small molecule 75 mg Oral
Subject Henatinib Small molecule 87.5 mg Oral
Subject Henatinib Small molecule 100 mg Oral

Indications

cancer